Core Viewpoint - Appili Therapeutics has successfully re-launched LIKMEZ™ (ATI-1501), a metronidazole oral suspension, and is actively pursuing funding opportunities to support its development programs and enhance its market position [2][3][14]. Group 1: Product Development and Market Position - LIKMEZ™ (ATI-1501) is the first FDA-approved, ready-to-use liquid oral suspension of metronidazole, specifically designed for patients who have difficulty swallowing tablets or are sensitive to taste [3][4]. - The re-launch of LIKMEZ follows new patent coverage extending to 2039, marking a significant milestone for the company and its partner, Saptalis Pharmaceuticals [2]. - Appili is focused on driving continued sales of LIKMEZ while advancing other product candidates, including ATI-1701 and ATI-1801 [3]. Group 2: Funding and Financial Performance - The company has submitted five non-dilutive funding proposals to the U.S. government, with a total potential value of up to US$125 million, aimed at supporting the development of critical infectious disease products [3][14]. - For the fiscal year ended March 31, 2025, Appili reported a net loss of CAD 2.6 million, which is an improvement from a net loss of CAD 3.8 million in the previous year, primarily due to increased government assistance and other income [19][20]. - As of March 31, 2025, the company had cash reserves of CAD 1.2 million, a significant increase from CAD 0.1 million a year earlier, indicating improved liquidity [21]. Group 3: Research and Development Progress - ATI-1701, a biodefense vaccine candidate for tularemia, has received approximately US$11.6 million in funding from the U.S. Air Force Academy and has shown promising results in providing protection against lethal tularemia [5][6]. - The company is actively pursuing additional funding and partnership opportunities for ATI-1801, a topical antiparasitic product that has received Orphan Drug Designation from the FDA [10][13]. - Appili has successfully completed technology transfer for the ATI-1701 manufacturing process, supporting future development activities [8].

Core Viewpoint - Globavend Holdings Limited has received approval-in-principle for up to $900,000 in non-dilutive government funding to support its expansion into the Chinese market, which is seen as a significant milestone for the company [1][3]. Group 1: Government Funding - The funding is provided by the Dedicated Fund on Branding, Upgrading and Domestic Sales (BUD Fund) from the Hong Kong government, aimed at helping local businesses scale operations and expand into new markets [2]. - The Hong Kong government has allocated approximately $770 million to the BUD Fund to assist enterprises in capturing opportunities from China's 12th Five-Year Plan [2]. Group 2: Company Expansion - The CEO of Globavend expressed confidence in the company's eligibility for the funding and emphasized the importance of this financial support for accelerating their expansion into China [3]. - Globavend has already established its business model in Australia, New Zealand, and Hong Kong, making the entry into China a natural progression [3]. - The company aims to leverage the funding to scale its operations without compromising its capital structure, especially as Australia is becoming a key logistics hub amid geopolitical tensions [3]. Group 3: Company Overview - Globavend Holdings Limited is an emerging e-commerce logistics provider offering end-to-end logistics solutions primarily for enterprise customers, including e-commerce merchants [4]. - The company provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, covering various logistics processes such as parcel drop-off, consolidation, air-freight forwarding, customs clearance, and final delivery [4].